Published in:
01-07-2008 | Contributions from International Congress
5.13 Arterial Hypertension and Hyperhomocysteinaemia with TT Polymorphism of the C677T Gene for the 5-10-Methylenetetrahydrofolate Reductase: Risk Factors able to influence Clinical Management of the Patent Foramen Ovale?
Authors:
A. Mazza, S. Zamboni, S. Cuppini, M. Armigliato, P. Rempelou, A. Camerotto, M. Gusella, A.C. Pessina, V. Tikhonoff, E. Casiglia
Published in:
High Blood Pressure & Cardiovascular Prevention
|
Issue 3/2008
Login to get access
Excerpt
Introduction. In subjects aged <55 years, the association between patent foramen ovale (PFO) and cryptogenetic cerebrovascular (CV) events is well established. In the clinical management of the PFO, a thrombophilic screening including homocysteinaemia (Hcy) determination and methylenetetrahydrofolate reductase polymorphism (MTHFR) evaluation for the C677T gene are recommended. …